Neogen (FRA:NG2) Payments of Debt: €-573.9 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NG2 Neogen Corp FRA:NG2
69 GF Score
Price €8.88
GF Value €10.62
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neogen Payments of Debt?

Neogen FRA:NG2 +3.67% 69 Payments of Debt is €-573.9 Mil as of Feb. 2026. GuruFocus rates FRA:NG2 with a GF Score™ of 69/100 and a GF Value™ of €10.62 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Neogen's Payments of Debt for the three months ended in Feb. 2026 was €-0.0 Mil.

Neogen's Payments of Debt for the trailing twelve months (TTM) ended in Feb. 2026 was €-573.9 Mil.

Neogen Payments of Debt Related Terms

Neogen Payments of Debt Historical Data

* Premium members only.

The historical data trend for Neogen's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neogen Payments of Debt Chart

Neogen Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -92.00 -0.39 -488.14

Neogen Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -487.96 -85.96 0.00 -0.02
FRA:NG2
69GF Score
Neogen Corp FRA:NG2
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neogen Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-573.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-573.9 Mil mean?
Neogen (FRA:NG2) has a Payments of Debt of €-573.9 Mil as of Feb. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Neogen and its competitors.
Is Neogen's Payments of Debt too high?
Neogen's current Payments of Debt is €-573.9 Mil. Overall, Neogen has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Payments of Debt compare to UFPT and ALMR?
Neogen's Payments of Debt of €-573.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Neogen and its competitors. Neogen's current Payments of Debt is €-573.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.62, compared to a current price of €8.88 — trading 16.4% below its estimated fair value. The current Payments of Debt is €-573.9 Mil. Neogen's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Payments of Debt is €-573.9 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neogen (FRA:NG2) Overvalued in 2026?

Based on GuruFocus' analysis, Neogen stock appears to be undervalued. The current stock price of €8.88 is trading 16.4% below its estimated GF Value™ of €10.62. GuruFocus considers Neogen to be Modestly Undervalued.

Key valuation signals for FRA:NG2:

  • Payments of Debt: €-573.9 Mil
  • GF Value™: €10.62 vs. price of €8.88 (16.4% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neogen Business Description

Other Exchanges NEOG:USANG2:Germany
Address 620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
69GF Score

Get the complete analysis for FRA:NG2

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.88
Price
€10.62
GF Value